Cancer treatments including administering IL-2 fusion proteins with modulated selectivity
US7462350B2 · kind B2 · utility
32Cited by
117References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 16, 2006 |
| Grant date | Dec 9, 2008 |
| Priority date | — |
| Expiry date | Oct 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.